Wakamoto Pharmaceutical Co.,Ltd. (TYO:4512)

Japan · Delayed Price · Currency is JPY

287.00

-1.00 (-0.35%)

Nov 13, 2026, 3:30 PM JST

Market Cap	9.99B +1.4%
Revenue (ttm)	9.43B -2.5%
Net Income	-222.00M
EPS	-6.38
Shares Out	34.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	3.00 (1.05%)
Ex-Dividend Date	Mar 30, 2027

Volume	6,900
Open	288.00
Previous Close	288.00
Day's Range	285.00 - 288.00
52-Week Range	240.00 - 380.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Wakamoto Pharmaceutical

Wakamoto Pharmaceutical Co.,Ltd. is engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. It operates through four segments: Pharmaceutical Business, Healthcare Business, Global Business, and Real Estate Leasing Business. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1929

Employees 403

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4512

Full Company Profile

Financial Performance

In fiscal year 2012, Wakamoto Pharmaceutical's revenue was 9.43 billion, a decrease of -2.45% compared to the previous year's 9.67 billion. Losses were -222.00 million, -47.76% less than in 2011.

Financial Statements